ITGB3 and neoplasm: In vivo, Cal+Cur treatment significantly reduced tumor onset and volume, Itgb3 expression, microvessel count, and tumor uptake of integrin-targeted biosensors, strongly suggesting an antiangiogenic promoting effect of the drug combination.